Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Pieter R. Cullis, Ph.D. FRSC, FNAI (USA), Scientific Director & CEO, NanoMedicines Innovation Network,  Canada’s National Centre of Excellence in nanomedicines; Professor, Department of Biochemistry and  Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the design and development of nanomedicines employing lipid nanoparticle  (LNP) technology for cancer therapies and gene therapies. This work has contributed to five drugs that have been approved by regulatory agencies in the U.S., Europe and Canada. Dr. Cullis has co-founded  ten biotechnology companies that now employ over 300 people, has published over 350 scientific articles and is an inventor on over 60 patents. He also co-founded the Centre for Drug Research and  Development, a Centre of Excellence for the Commercialization of Research (now AdMare) in 2004, the  Personalized Medicine Initiative (PMI) in 2012 and the NanoMedicines Innovation Network in 2019. Dr.  Cullis was elected a Fellow of the Royal Society of Canada in 2004 and was also awarded the Prix Galien,  Canada’s premier prize for achievements in pharmaceutical R&D, in 2011. Two recently approved drugs that are enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is BNT162b2, the COVID-19 vaccine developed by Pfizer/BioNTech that has now (December 2020) been approved in Canada, the USA, the UK and Europe. It is anticipated that more than 1.3B doses of BNT162b2 will be administered worldwide in 2021.

Dr. Helen Messier has dedicated most of her career to harnessing data to bridge the translational gap in medicine. She has cultivated a unique expertise in seamlessly integrating multi-omic data and digital health technologies into real-world clinical care, to enable patients to realize the beneficial potential of biomedical technologies.

Dr. Messier holds a Bachelor of Science with Honors in Genetics and a Ph.D. in Molecular Immunology from the University of Alberta. Following her doctoral studies, she completed post-doctoral studies at the La Jolla Institute for Allergy and Immunology in San Diego, CA, and received her MD from the University of Calgary. She is certified in family medicine.

Beyond clinical practice, Dr. Messier has left an indelible mark as a notable innovator and healthcare entrepreneur. Alongside her roles on various medical and scientific advisory boards, she founded a national network of concierge medical practices in Canada, served as the Medical Director of Genomics at Human Longevity Inc, and played a pivotal role as the inaugural Chief Medical Officer of Viome.

In her current role as the Chief Medical and Science Officer at Fountain Life, Dr. Messier is delighted to bring her extensive experience and profound knowledge to further advance her mission in expanding proactive and preventative medicine. In addition to leading the company’s clinical and scientific programs, Dr Messier is establishing Fountain Life University, to train Fountain Life certified practitioners and lead the effort to gain insights and publish findings from Fountain Life’s vast amount of data.

Joby McKenzie is the Managing Director of Teladoc Health in Canada responsible for all strategy and operations, growing whole person virtual care to empower Canadians to live healthier lives. Dr. McKenzie also volunteers as a Board Director at Mackenzie Health overseeing their strategic, quality and financial plans and decisions.

Previously, Dr. McKenzie served as the Managing Director at Babylon Health in Canada, where she led the exponential adoption of virtual primary care across Canada. Prior to that, she held executive roles at LifeLabs (medical diagnostic services) in business development, post-merger integration, government relations and strategy and was a consultant at the Boston Consulting Group (BCG) where she worked with clients in healthcare and financial services and helped them to increase shareholder value. Dr. McKenzie was also an international professional basketball player and Canadian national athlete including qualifying for the 2000 Olympics and receiving a silver medal at the 1999 PanAm Games.

Dr. McKenzie has an MBA from the Ivey School of Business, a Doctor of Philosophy in Molecular and Medical Genetics from the University of Toronto and a Bachelor of Science in Molecular Biology and Biochemistry from Simon Fraser University.

As Vice President, Product & Platforms, Channels and Customer Experience at LifeLabs, Judy’s current focus centers on engaging in purposeful design and delivery of end-to-end health experiences that reinforces LifeLabs’ value proposition and sustains customer loyalty with the goal to improve health outcomes for Canadians.

As an active member of the Toronto design community, Judy serves on the Rotman Design Initiative Advisory Board, has taught Business Design to undergraduate students at the Ted Rogers School of Management and currently trains women entrepreneurs and diverse groups with WE-Hub (Women’s Entrepreneurship Hub) and ADaPT (Advanced Digital & Professional Training), respectively.

Dr. Zia Poonja is an oncologist, researcher, health enthusiast, and founder of companies specializing in health optimization. He is passionate about prevention and advocates for people to recognize their agency in their quality of life.

Zia completed a BSc in Human Physiology followed by his MD at the University of Saskatchewan. Subsequently, he completed a residency in Internal Medicine at the University of Alberta and a fellowship in Medical Oncology at the University of British Columbia (UBC). Zia currently practices oncology at BC Cancer in Victoria and is an actively involved founder and Chief Medical Officer of MyHealthspan and PrehabRx.

Zia holds faculty positions at UBC and the University of Victoria and serves the community in various volunteer positions. He is a proud father of two and enjoys powerlifting and running in his spare time.

Dr Rachael Ritchie is passionate about helping people, companies and communities embrace–and enable–innovation for impact. She is the Director of Innovation at Vancouver Coastal Health (VCH) where she’s working to establish a robust innovation ecosystem to enable staff and medical staff to generate and translate new ideas and advances in science and tech into every-day practice. She has worked in roles across the innovation continuum from research to commercialization, funding to policy to develop a rich understanding of innovation systems.

Rachael has a doctorate in Clinical Medicine from Oxford University and conducted medical research at John Radcliffe Hospital (Oxford, UK) and Boston Children’s Hospital (Harvard, USA) before transitioning to broader strategic roles in France and Canada at the Organization for Economic Co-operation and Development, Genome BC, and the Centre for Drug Research and Development.

As President and Chief Executive Officer, Suzanne Gill leads Genome BC in applying the power of genomics in ways that better the lives of all British Columbians. Suzanne has been at the forefront of catalyzing sustainable, public-private partnerships across the life sciences ecosystem for more than 20 years. She provides a wealth of experience in the Canadian innovation environment, including economic development and stakeholder relations, and in helping to shape and implement strategy for organizations at the nexus of research, innovation and commercialization.

Suzanne is passionate about the important work of integrating genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences, helping BC rise to the challenges of the 21st century.

Working with our partners, Suzanne’s focus is on building upon Genome BC’s successes in precision health, natural resources and education while growing BC’s thriving life sciences research and innovation ecosystem. Genomics has proven to be an important tool in the diagnosis and treatment of cancer, rare diseases and the prevention of adverse drug reactions. Genomics is also providing new and transformative ways to address BC’s environmental challenges, such as determining which plants and trees will be better able to adapt to new environmental conditions as well as identifying and managing invasive pests and disease-causing pathogens that pose threats not only to forests but also many fruit crops.

Previously, Suzanne was a founding executive as the Vice President, Government Relations and Public Affairs with the Digital Supercluster (2018-2022), an industry-led organization that aims to accelerate economic growth and position Canada for global leadership in transformative digital technologies. In addition to fostering an essential relationship between industry, academia and government, she also led the development and launch of Digital Supercluster’s inaugural Capacity Building Pilot Program aimed at connecting employers to job ready digital talent.

Prior to joining the Digital Supercluster, Suzanne was at Genome BC for over a decade and last held the role of Vice President, Corporate Development, responsible for corporate strategy, corporate performance management and government relations. She moved to BC following her work at the Ontario Genomics Institute as part of the start up team and was responsible for oversight of a $300 million research portfolio at the time when Canada was making its first large scale investments in research in the sector.

Suzanne holds an MSc degree from the University of British Columbia and an MBA from the Schulich School of Business at York University in Toronto. She has been on the Board of Directors of Innovate BC since 2018.

Dr. Darryl Knight brings over 20 years’ experience as an academic leader and medical researcher to Providence Health Care (PHC). He obtained his PhD from the University of Western Australia in 1993. In 2004, he was recruited to the University of British Columbia (UBC) and PHC as the Canada Research Chair in Airway Disease. He was recruited back to Australia in 2013 as Head, School of Biomedical Sciences and Pharmacy at the University of Newcastle, before being recruited back to Canada in 2019 as Vice President, Research and Academic Affairs, Providence Health Care, President, Providence Health Care Research Institute, Associate Dean, Research, Faculty of Medicine, UBC and Visiting Professor, Nanyang Technological University, Singapore.

Dr. Knight’s research career has focused on understanding how abnormal epithelial cell-fibroblast interactions influence the severity and chronicity of respiratory diseases and impact on treatment. He has published over 200 peer-reviewed manuscripts and book chapters (h-factor 73; 15,750 citations) and is co-inventor on 13 patents. He has a strong track record of obtaining research grant funding (>$25M) and been primary supervisor for seven post-doctoral fellows, 17 PhD and two MSc students and 20 Graduate students. He sits on several journal editorial boards as well as the board of Research Canada. Dr. Knight is passionate about building teams and networks to solve complex health related problems.

Dr. Terri Petkau serves as the Director of Operations at Polymorphic Biosciences, where she oversees initiatives in drug delivery, gene therapy, and personalized medicine that bridge scientific discovery with translation into real-world applications. Terri completed her PhD in Genetics at the University of British Columbia, where her research focused on gene therapy approaches for neurodegenerative diseases. More recently, Terri has gained broad expertise in aging biology and its translation into clinical practice. Terri’s leadership reflects Polymorphic Biosciences’ commitment to transforming innovative research into actionable strategies, fostering collaborations to accelerate breakthroughs in personalized healthcare and longevity science.

Dr. Darryl Knight brings over 20 years’ experience as an academic leader and medical researcher to Providence Health Care (PHC). He obtained his PhD from the University of Western Australia in 1993. In 2004, he was recruited to the University of British Columbia (UBC) and PHC as the Canada Research Chair in Airway Disease. He was recruited back to Australia in 2013 as Head, School of Biomedical Sciences and Pharmacy at the University of Newcastle, before being recruited back to Canada in 2019 as Vice President, Research and Academic Affairs, Providence Health Care, President, Providence Health Care Research Institute, Associate Dean, Research, Faculty of Medicine, UBC and Visiting Professor, Nanyang Technological University, Singapore.

Dr. Knight’s research career has focused on understanding how abnormal epithelial cell-fibroblast interactions influence the severity and chronicity of respiratory diseases and impact on treatment. He has published over 200 peer-reviewed manuscripts and book chapters (h-factor 73; 15,750 citations) and is co-inventor on 13 patents. He has a strong track record of obtaining research grant funding (>$25M) and been primary supervisor for seven post-doctoral fellows, 17 PhD and two MSc students and 20 Graduate students. He sits on several journal editorial boards as well as the board of Research Canada. Dr. Knight is passionate about building teams and networks to solve complex health related problems.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Cameron Burke is a seasoned operator, and advisor with over 20 years of experience in scaling technology companies and leading them from concept to successful exits. He has co-founded and exited two tech companies and scaled another to IPO. Cam’s expertise spans capital raising, operations, go-to-market (GTM) strategy, and deal-making, making him a versatile leader with a proven track record in accelerating growth.

Throughout his career, Cam has worked alongside some of Canada’s top innovators and investors, gaining deep expertise across various sectors, including Digital Health/Healthtech, CleanTech, FinTech, AI, and AI. His ability to support the financial and strategic needs of entrepreneurs at every stage of their business journey has made him a trusted advisor in the tech ecosystem.

Cam holds a degree from the University of Victoria and currently serves as Partner at Fort Capital Partners, where he leads their Technology & Innovation Banking practice. Prior to joining Fort Capital, Cam held leadership roles at PwC Canada, Hootsuite, and several other tech companies. His background in corporate development, M&A, and value creation has been instrumental in driving growth and international expansion for a wide range of businesses.

In addition to his professional achievements, Cam is actively involved in the community as a Board Director for the Museum of Vancouver, The Seedlings Foundation and has previously served as Vice Chairman & Treasurer for BC Tech and UNESCO. He is a regular contributor to publications such as Betakit and the Canadian Healthcare Network, and was recognized as one of Business in Vancouver’s Top 40 Under 40.

Terry has an impressive network and track record of success in senior roles in corporate development and operations, with industry experience in telecommunications, software and consumer electronics. He’s the founder of Amicita Capital, an early-stage venture fund investing in the future of work. Terry is a Canadian at heart, having played a key governance role in C100 – a non-profit, member-driven association of Canadian thought-leaders committed to supporting and accelerating the innovation economy in Canada. Terry also has extensive international experience leading successful partnership and M&A activities in Asia and Europe for multinationals like British Telecom, Nokia and Microsoft, as well as high growth startups like Checkr. Terry holds a CLB (Bachelor of Civil Law) and LLB from McGill University and is a member of the Institute of Directors in the UK, the Law Society of England and Wales, and the Law Society of Upper Canada. He lives in California and enjoys cycling, travel and competitive sailing.

Brenda is Founder and Managing Partner of the Relentless Venture Fund, a North American life sciences health technology fund.

She is a member of DIGITAL’s Tech Leadership and Horizon-AI project selection committees (former Supercluster) and serves as chairperson for the Canadian Medical Isotope Ecosystem Development Fund selection committee.

Brenda is an EIR for the Life Sciences BC ‘Investor Readiness Program’, and an associate for Creative Destruction Labs.

Her industry honours include being declared one of BC’s Most Influential Women in Finance, one of the 500 most influential business leaders in British Columbia, and in 2023, “Mentor of the Year” for CDL-Vancouver.

An experienced health investor and board director, Brenda has led dozens of private and public transactions as venture capitalist and angel investor.

Brian is the President of PHC Ventures and also holds the role of CFO and VP Health Informatics for Providence Health Care. Before Brian joined PHC in 2019, he spent 25 years dedicated to roles that allowed him to leverage technology and applying innovative solutions to improve and transform organizations. Previously, Brian served as CFO & VP Client Experience at Technical Safety BC, where he played a pivotal role in transforming the organization into an AI-enabled regulatory authority. He also served as CFO of Aegis Mobility, a start-up provider of patented, distracted driving software for mobile devices. He was CFO & GM for Cityfone Telecommunications and oversaw its 5-fold growth and eventual acquisition by Rogers Communications. Brian holds a CPA (CA) from the Certified Public Accountants of BC, a CPA from the University of Illinois, and a BA in Business Administration from Simon Fraser University.

Joby McKenzie is the Managing Director of Teladoc Health in Canada responsible for all strategy and operations, growing whole person virtual care to empower Canadians to live healthier lives. Dr. McKenzie also volunteers as a Board Director at Mackenzie Health overseeing their strategic, quality and financial plans and decisions.

Previously, Dr. McKenzie served as the Managing Director at Babylon Health in Canada, where she led the exponential adoption of virtual primary care across Canada. Prior to that, she held executive roles at LifeLabs (medical diagnostic services) in business development, post-merger integration, government relations and strategy and was a consultant at the Boston Consulting Group (BCG) where she worked with clients in healthcare and financial services and helped them to increase shareholder value. Dr. McKenzie was also an international professional basketball player and Canadian national athlete including qualifying for the 2000 Olympics and receiving a silver medal at the 1999 PanAm Games.

Dr. McKenzie has an MBA from the Ivey School of Business, a Doctor of Philosophy in Molecular and Medical Genetics from the University of Toronto and a Bachelor of Science in Molecular Biology and Biochemistry from Simon Fraser University.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

Dr. Lyle Oberg has a long history of providing public service to Albertans.

Born and raised in Forestburg, Alberta, Dr. Oberg completed his Doctorate of Medicine at the University of Alberta in 1983. He stayed in rural Alberta, beginning his medical practice in Cold Lake, and then moving to Brooks. During that time, he performed surgery, anesthesia, emergency medicine and obstetrics.

In 1993, he ran for public office and was elected as the MLA for Bow Valley. Dr. Oberg served as an MLA for 15 years and held numerous posts, most notably as the Minister of Social Services, Minister of Learning, Minister of Infrastructure and Transportation, and Minister of Finance.

Dr. Oberg is also an Honorary Chief of Treaty 7, an honor that was given to him for his work in Indigenous education. Dr. Oberg is a former Board Member of the TSX listed Olympia Trust and CareRx, a present Board Member of Yorkville Asset Management, Toronto; Eyam Vaccines and Immunotherapeutics, Vancouver; and Promethean Biopharma, Sydney, Australia. He is also Vice Chairman of Vancouver Premier College.

He and his wife Evelyn have four adult children and nine grandchildren. He enjoys hunting, boating and home renovation projects.

Bringing more than 35 years of experience in healthcare-related industries, Dianne currently serves as the Senior Vice President of the Government Division at Alberta Blue Cross. With a strong track record of establishing strategic and innovative partnerships, she is known for challenging the norm rather than moving with it, both at work and in her community. This coupled with her natural intuition and curiosity has led to groundbreaking initiatives in support of improved health and wellness outcomes for the communities she serves.

Dianne works closely with senior government officials—both provincial and across Canada—and a broad sector of the health industry including, pharmaceutical and medical, to foster effective working relationships. Focused on delivering quality results coupled with strong leadership, Dianne is highly engaged as both a director and board chair for various organizations and foundations. Dianne is currently actively serving as a board director for The Royal Alexandra Hospital Foundation, the Women and Children’s Health Research Institute and Edmonton Health Cities.

Dianne strives to make a positive difference in peoples’ lives. With her certification as an Executive Coach through Royal Roads University, she works to inspire and empower individuals to tackle challenges with gusto and to never accept anything less than incredible as an outcome. She looks forward to an engaging dialogue with you.

Cam Linke is the CEO of the Alberta Machine Intelligence Institute (Amii), one of Canada’s three centres of AI excellence as part of the Pan-Canadian AI Strategy. He is a longtime leader in Edmonton’s technology and startup community. Over the past 10 years, he has worked as a CEO, investor, community builder, product manager, software entrepreneur, academic, and developer. Past roles include Co-founder of Startup Edmonton, Founder of Flightpath Ventures, CEO of Touch Metric, Product Manager at Nexopia.com, and Founder of DemoCamp Edmonton. Linke is a sought-after speaker and mentor and has been recognized as Avenue Magazine’s Top 40 Under 40. He is also an artificial intelligence researcher, currently studying under Dr. Richard Sutton and Dr. Adam White. His research, which focuses on AI adapting behaviours to improve their own self-learning, has been published at top conferences.

Dr. Zsuzsanna Hollander is a passionate leader driven to advance human health and wellness by maximizing the value derived from data through data management and data science. As the Director of Data Science at Genome BC she leads the implementation of the organization’s Data Science strategy. She oversees various projects in data management, data governance, and information processes, and builds relationships with key stakeholders from private industry, government, and academia. Prior to joining Genome BC, she was the Chief Data Officer at the PROOF Centre of Excellence where she worked for over 15 years. During that time, she gained expertise in translational research, machine learning, data management, and database development. She co-authored >50 scientific papers and co-invented 2 patents in the genomics and molecular diagnostics fields.

RGS Management Consultants specializes in advising and leading privacy programs within both private and public sector companies. RGS Management services focus on providing practical, cost-effective operational solutions that meet consumer, corporate, and regulatory expectations while demonstrating accountability and compliance with privacy laws.  Having served as Chief Privacy Officer at TD Bank, HSBC, and the University Health Network, she has the unique experience of having led privacy programs in both the private and public sectors and was a privacy regulator through an Executive interchange program with the Privacy Commissioner of Canada’s office.

Abhinav(“Abhi”) Kalra is an Executive Vice-President at Canada Health Infoway. Abhi Kalra is a health care technology leader with extensive public-private sector experience in designing transformation strategy for the healthcare vertical and delivering large scale, complex, outcome-based, multi-year digital transformational programs across North America, Europe and Asia. In his current role with Infoway, he leads the pan-Canadian strategy to advance our connected care system through the execution of Digital Health Interoperability program, with the goal of improving the patient and provider experience and enabling Canadians with access to their health information and improved health outcomes. Prior to this, he played a key role in defining, designing and delivering first phase of Infoway’s national e-prescribing service.

Abhi held key leadership roles across North America, Europe & Asia with large corporations like Shoppers Drug Mart, Oracle, and General Electric. In these roles, Abhi built long range strategy, executed large scale multi-year transformational programs, and driven revenue growth and operational efficiency by introducing new technology products and building innovative digital solutions.

Allan Noordvyk is the Executive Director of Health Informatics at Providence Health Care. In that role he is responsible for charting the digital roadmap for the enterprise, delivering current and relevant data to drive decisions, and supporting continuous improvement and innovation through the introduction of useful new technologies and research systems infrastructure. Before coming to PHC, Allan spent almost 3 decades in the medical imaging industry, developing world-leading solutions for image management, workflow and visualization while working for ALI Technologies, McKesson, and Change Healthcare. Allan has been an organization lead on multiple successful Canadian Digital Technology Supercluster project applications including the Intelligent Network for Point-of-Care Ultrasound (IN-PoCUS). At the provincial level, Allan is co-chair of the BC Health Data Platform (HDP) operations committee. He chaired the Digital Image Communication in Medicine (DICOM) working group 17 that introduced 3D printing models to the industry standard. During his career Allan has been granted 3 patents in the health technologies.

Pamela Snively is the Chief Data & Trust Officer at TELUS. She leads the team responsible for privacy governance and data ethics, along with data management and a number of compliance functions, including the Anti-bribery & Corruption and Competition Law programs. Pam approaches overall data governance through the lens of customer trust, leveraging TELUS’ Customer First principle to drive the organization’s commitment to privacy and data ethics.

Pamela was the recipient of the 2017 Ontario Bar Association’s Karen Spector Memorial Award for Excellence in Privacy Law. She participates in a number of national and international think-tanks and governance bodies related to privacy and data governance, including serving as a Board member for the Information Accountability Foundation and on the Privacy and Data Advisory Committee for the Canadian Marketing Association. She is also a founding member and Chair of Canada’s Business Privacy Group, a working group made up of some of Canada’s leading privacy professionals and industry associations focused on building trust in Canada’s digital ecosystem and legislative regime.

Pamela is a frequent speaker on privacy and data ethics and she actively encourages other organizations to join her in her mission to earn and elevate consumer trust in our digital ecosystem.

Diane Finegood is a Professor and Fellow in the Morris J. Wosk Centre for Dialogue at Simon Fraser University where she teaches in the Semester in Dialogue. Her career has spanned a broad range of disciplines and leadership roles. She served as President & CEO of the Michael Smith Foundation for Health Research, Executive Director of the Canadian Health Services and Policy Research Alliance and inaugural Scientific Director of the Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes. Diane is internationally recognized with scholarly work in a range of disciplines including pathogenesis of type 1 and type 2 diabetes, application of mathematical modeling to physiological systems, cross sector partnership, knowledge mobilization, systems thinking and complex adaptive systems.

Holly is a PhD level trained ethicist and research consultant. She serves as an ethicist on a US-based IRB and is an Adjunct Professor in the Faculty of Health Sciences at Simon Fraser University. She has worked as a consultant for Health Canada, the Public Health Agency of Canada, and the CIHR Ethics Office and her work has been published in a variety of journals including CMAJ, Trends in Neurosciences, and Cell Stem Cell. Her current Director role at the Provincial Health Services Authority (PHSA) of British Columbia reflects PHSA’s commitment to strengthening its research enterprise in support of its fundamental mandate to conduct world class research as an academic health science organization with an integrated mandate to deliver care, conduct research, and train tomorrow’s providers.

Visionary leader committed to transforming health care systems and implementing innovative solutions that create sustainable, high quality services for future generations.

Jim has experience in senior leadership roles in all 4 Western provinces and in leading several national health care initiatives particularly focused on innovative solutions that deliver a substantive clinical value. He has championed “Choosing Wisely” and “Personalized Medicine” developing provincial strategies for both MB and BC. Jim’s leadership positions include: BC’s first Chief Provincial Diagnostics Officer leading the development, implementation, and evaluation of the province-wide pathology and medical laboratory service delivery model; CEO of Diagnostic Services Manitoba leading the transformation of provincial diagnostics; as well as COO of Shared Health, Executive Director in SK, and Healthy System and Business Advisor in AB. Jim is currently the Chief of Research Administration and Operations, Paul Albrechtsen Research Institute, Cancer Care Manitoba pursuing his passion for research and innovation that have real positive impacts for patient care and outcomes.

Steven is a partner at INQ Law and a senior legal and privacy professional with a focus on data sharing frameworks and strategic data governance and stewardship.

He served as General Counsel & Chief Privacy Officer at Vancouver Coastal Health (VCH) for over 12 years. In this capacity, he led the development of the General Health Information Sharing Agreement (GHISA), a unified, overarching agreement signed in 2013 between the BC Ministry of Health and all BC health authorities. Today, the GHISA continues to be the foundational legal, policy and data governance framework that governs almost all sharing of health information across the province for provision of care, research, quality improvement and healthcare planning. He also played a key role in influencing recent changes to the Freedom of Information and Protection of Privacy Act that reformed its data residency provisions to better support health innovation and technology adoption.

Most recently, prior to joining INQ Law, he served as VCH’s Chief Data Governance Officer where he worked to transform how data is strategically governed and managed so that higher quality data is made accessible more quickly to clinicians, researchers and administrators to deliver better care and improve our healthcare system, while enhancing data security, privacy and ethical use of health data.

In addition to a Bachelor of Laws degree from UBC, Steven holds a Masters in E-Business law from Osgoode Hall Law School and a Bachelor of Commerce degree from UBC.

Mary is a visionary healthcare executive with 20 years of diverse senior management experience within the British Columbia provincial healthcare network, including 6 years as the CEO of Vancouver Coastal Health. She is known as a tireless advocate working to accelerate the transformation of the Canadian healthcare system into a modern and sustainable service. Mary served as an executive leader in the regionalization of British Columbia health services since its inception in 2000 and has deep experience in leveraging the benefits of integration to improve health outcomes and reduce costs. Mary possesses a proven talent for both strategic development and tactical execution that spans strategy, operations, financial and facilities management, and organizational transformation.

She has led healthcare innovation in both the clinical and technology realms by paying particular attention to the systems and culture required to drive change. She was one of two CEO co-leads responsible for implementing, at the time, the largest cross-organizational clinical software implementation in Canada. Additionally, she has a career history of success in working closely with physicians, varied health professions and frontline personnel to achieve sustained improvements in patient outcomes.

Mary has held successive executive leadership roles at Vancouver Coastal Health and Fraser Health. She also served as Associate Deputy Minister and Innovation Executive in Residence at the BC Ministry of Health and Executive Advisor within the healthcare practice of Deloitte Canada. Prior to her career in healthcare, she spent 9 years leading operations at INSEAD business school in France, and 5 years in high tech manufacturing as a plant manager in the United States. Mary’s passion and expertise in system change began with her two degrees in Industrial Engineering (B.S. and M.S.) from West Virginia University and her MBA from Harvard University.

Mary has served on many healthcare and social purpose Boards including Vancouver Foundation, Telus Community, Michael Smith Foundation, Genome BC, and Street to Home, among others. She was named one of Canada’s Top 25 CEOs by Glassdoor in 2019 and one of Canada’s Most Powerful Women in 2013 and 2014.

Dr. Justin Hall is an emergency medicine physician and Chief of the Department of Emergency Medicine at Sunnybrook Health Sciences Centre, the Medical Director for Toronto’s Virtual Emergency Department, and an Affiliate Scientist at Sunnybrook Research Institute. He is an Assistant Professor in Quality and Innovation in the Division of Emergency Medicine, Department of Medicine, Temerty Faculty of Medicine at the University of Toronto.

He is the Co-Chair of the Canadian Triage and Acuity Scale (CTAS) National Advisory Committee, a joint collaboration of the Canadian Association of Emergency Physicians (CAEP) and the National Emergency Nurses Association (NENA). He serves as Co-Chair for the Ontario Health Clinical Advisory Committee for Virtual Urgent Care and as a member of the CAEP Artificial Intelligence Special Interest Group and CAEP Choosing Wisely Canada Working Group. Dr. Hall’s academic interests include resource appropriateness, virtual care and digital health solutions including the use of artificial intelligence and machine learning, and capacity building related to quality improvement and patient safety.

Dr. Kendall Ho, Director of Digital Emergency Medicine at the University of British Columbia’s Faculty of Medicine, practices clinically at the Vancouver General Hospital.

Dr. Ho’s research area is in eHealth – the innovative application and evaluation of modern information and communication technologies in health research, education, and health practice. Examples of his research initiatives include the use of biosensors, social media and text messaging and the development of the next generation of wearable sensors.

He conducts benefits evaluation of various aspects of eHealth in partnership with health policy makers, and engages the general public and health professionals in eHealth uptake and adoption. He chairs the Royal College of Physicians and Surgeons of Canada CanMEDS 2015 Expert Working Group, is a member of the College’s ePortfolio Advisory Committee, and has been a member of the Association of Faculties of Medicine of Canada eHealth Education Committee. He is a past Board member of COACH – Canada’s Health Informatics Association. He leads the development and implementation of the eHealth-informatics curriculum in UBC Medical School. He chairs the annual eHealth Innovations and Technology Showcase (eHITS) conference in B.C. to engage health professionals in eHealth adoption. He is a collaborator with the World Health Organization Global eHealth Observatory and the Pan American Health Organization Department of Knowledge Management.

Ronan is a seasoned healthcare consultant and leader with over 20 years of experience in transforming healthcare organizations and systems in Canada and the UK. Ronan has served as a contracted Assistant Deputy Minister and Independent Alberta Surgical Recovery Lead with Alberta Health. In Manitoba, Ronan was the Chief Operating Officer of Health Sciences Centre (HSC) Winnipeg. Ronan previously led KPMG’s Canadian National Healthcare Practice on Cost Improvement and Transformation supporting clients across Canada.

Prior to moving to KPMG, Ronan formed part of a senior leadership team which established EY Canada’s National Healthcare Practice and led nationally on cost optimization. Ronan has served on numerous boards of not-for-profit organizations, including the Federation of Irish Societies.

Telemedicine/Telehealth
Ronan was the policy lead for Telecare in the English Department of Health (2006-08) and in 2010, led the EY delivery team for what was then the largest Telehealth pilot in Europe which involved the redesign of care pathways for CHF, COPD and Type 2 Diabetes and the design of a “care at home: model. Ronan also co-authored in 2010, for EY Global the White Paper “When Remote Care is Core” and led program evaluations of Remote Patient Monitoring initiatives for both the European Union and Canada Health Infoway. More recently, Ronan supported the development of Manitoba’s Virtual COVID 19 Program and proposed expansion for patients with COPD and CHF.

Neil Sharma, Chief Commercial Officer at Swift Medical, is a seasoned digital health executive with a proven global track record of scaling successful businesses and driving innovation for a few decades. For the last many years, he has immersed himself in various aspects of healthcare with digital solutions on SaaS platforms. At Swift Medical, he is spearheading the market adoption of digital and AI-enabled wound care solutions. Under his leadership, the company has reached over 50 million patient assessments and expanded its reach to 4,800 healthcare facilities. Previously he held leadership positions at various startups and corporate companies where he brought expertise in go-to-market strategies and change management and leveraged technology to improve patient outcomes.

Presently, Dr. Lopez-Correa is the Chief Scientific Officer (CSO) at Genome Canada. As CSO, she is taking genomics to the next level in Canada, by advancing mission driven initiatives using genomics to solve the most pressing global challenges. Previously, she was Executive Director of the Canadian COVID19 Genomics Network (CanCOGeN), a $40M initiative to advance the use of genomics to help us understand and control the COVID19 pandemic. She also held the position of COO at Ruta N Medellin, driving innovation ecosystems to advance social and economic development in Colombia and Latin America. Prior to that, Dr. Lopez-Correa was the CSO at Genome BC (2016-2019) and at Genome Quebec (2008-2015) where she was instrumental in developing competitive teams for national and provincial research and innovation initiatives raising the profile of Canadian genomics on the global stage. Dr. Lopez-Correa has also held leadership positions at deCODE Genetics, and Eli Lilly and has played advisory roles at the European Commission, Innovative Medicine Initiatives and other private and public sector entities working in the application and implementation of genomics technologies. As part of her commitment to international development, Dr. Lopez-Correa has led several initiatives aimed at demonstrating the impact of genomics and innovation in developing countries. She is also fully committed to advance equity, diversity and inclusion, with a particular interest in gender equity in science. Dr. Lopez-Correa has been recognized with several awards: in 2017 she received the Canadian Senate 150th Anniversary Medal, in 2013 she was recognized by National Order of Merit Award in the Rank of Officer from the Republic of Colombia.

Dr. Lopez-Correa holds an MD from the Universidad Pontificia Bolivariana in Colombia, an MSc in Human Genetics from Paris V University in France, a PhD in Medical Sciences from the KULeuven in Belgium, and a mini-MBA from McGill University in Canada.

Diane Finegood is a Professor and Fellow in the Morris J. Wosk Centre for Dialogue at Simon Fraser University where she teaches in the Semester in Dialogue. Her career has spanned a broad range of disciplines and leadership roles. She served as President & CEO of the Michael Smith Foundation for Health Research, Executive Director of the Canadian Health Services and Policy Research Alliance and inaugural Scientific Director of the Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes. Diane is internationally recognized with scholarly work in a range of disciplines including pathogenesis of type 1 and type 2 diabetes, application of mathematical modeling to physiological systems, cross sector partnership, knowledge mobilization, systems thinking and complex adaptive systems.

Michael Green has dedicated his professional life to innovation in advancing the digital health agenda, creating jobs, and stimulating economic growth — all while ensuring higher-performing health systems and improving patient outcomes.

Serving as President and CEO of Canada Health Infoway since 2014, he has overseen the organization’s leadership in driving better access to health data and services to enable faster, more effective, and more efficient delivery of care. With a strong background in health leadership, Green has a proven track record of using innovative technologies to transform the health sector.

Green led the organization through the successful development and rollout of PrescribeIT®, Canada’s e-prescribing service. First introduced in 2017, PrescribeIT® now enables millions of Canadians to have their prescriptions sent electronically — and securely — to their pharmacy of choice.

Currently, Green is leading Infoway’s development of the Shared Pan-Canadian Interoperability Roadmap, which articulates strategies toward a modernized connected care system by improving access to data at the point of care, ensuring patient access to their own health information, and improving coordination and collaboration across care settings.

Green’s expertise and leadership have earned him recognition both nationally and internationally. He is a sought-after speaker on the topics of digital health and interoperability, and he has received honours for his contributions to health care.

Follow @MGreenonHealth

Frank is a seasoned product executive with extensive expertise in delivering innovative content-driven products and SaaS solutions. With a career that spans several decades, Frank has established himself as a results-oriented leader, continuously achieving success and ensuring market acceptance.

As EVP, Petal he excels in defining product vision, driving product development, and executing go-to-market strategies that align with business objectives. With a focus on operational excellence, Frank streamlines processes, enhances quality assurance, and improves efficiencies to promote growth. A strong leader, he builds high-performing, diverse teams and mentors talent to achieve optimal results. Frank’s strategic acumen, customer-centric approach, and deep industry knowledge make him a valuable asset in transforming organizations and driving revenue growth.

Soyean Kim currently works as the Head of Product at the Centre for Infectious Disease Genomics and One Health (“CIDGOH”) at Simon Fraser University. CIDGOH focuses on infectious disease management through a One Health Lens; a multi-sectoral approach involving human and animal health leveraging advanced computational approaches and innovative knowledge engineering. As a data analytics leader, Soyean has over 18 years of experience working in multiple domains, including consulting, private utility, public health, and government and non-profit organizations. Soyean is a certified Cloud professional and an accredited statistician (P.Stat.). Most recently, Soyean worked as the Director of Digital Products at Providence Health Care where her team focused on leveraging technology solutions to support hospital operations in addition to supporting Canada’s Digital Technology Supercluster to develop novel and innovative digital health applications.

Presently, Dr. Lopez-Correa is the Chief Scientific Officer (CSO) at Genome Canada. As CSO, she is taking genomics to the next level in Canada, by advancing mission driven initiatives using genomics to solve the most pressing global challenges. Previously, she was Executive Director of the Canadian COVID19 Genomics Network (CanCOGeN), a $40M initiative to advance the use of genomics to help us understand and control the COVID19 pandemic. She also held the position of COO at Ruta N Medellin, driving innovation ecosystems to advance social and economic development in Colombia and Latin America. Prior to that, Dr. Lopez-Correa was the CSO at Genome BC (2016-2019) and at Genome Quebec (2008-2015) where she was instrumental in developing competitive teams for national and provincial research and innovation initiatives raising the profile of Canadian genomics on the global stage. Dr. Lopez-Correa has also held leadership positions at deCODE Genetics, and Eli Lilly and has played advisory roles at the European Commission, Innovative Medicine Initiatives and other private and public sector entities working in the application and implementation of genomics technologies. As part of her commitment to international development, Dr. Lopez-Correa has led several initiatives aimed at demonstrating the impact of genomics and innovation in developing countries. She is also fully committed to advance equity, diversity and inclusion, with a particular interest in gender equity in science. Dr. Lopez-Correa has been recognized with several awards: in 2017 she received the Canadian Senate 150th Anniversary Medal, in 2013 she was recognized by National Order of Merit Award in the Rank of Officer from the Republic of Colombia.

Dr. Lopez-Correa holds an MD from the Universidad Pontificia Bolivariana in Colombia, an MSc in Human Genetics from Paris V University in France, a PhD in Medical Sciences from the KULeuven in Belgium, and a mini-MBA from McGill University in Canada.

MICHAEL HARVEY was appointed to a six-year term as BC’s Information and Privacy Commissioner by unanimous motion of the Legislative Assembly in May 2024.

From 2019 until to his appointment, Michael served as the Information and Privacy Commissioner for Newfoundland and Labrador. In early 2015, he led the implementation of the new Access to Information and Protection of Privacy Act, 2015. Then as Assistant Deputy Minister of Policy, Planning and Performance Management in the Department of Health and Community Services in August 2015, he was responsible for the ongoing statutory review of the Personal Health Information Act.

Michael served as co-chair of Canada Health Infoway’s Privacy Forum and was appointed by the federal government to the Expert Advisory Group on a pan-Canadian Health Data Strategy. He holds an International Baccalaureate from the United World College – USA, a BA (Hons) in Political Science from Memorial University, a MA in Political Studies from Queen’s University and an Executive Certificate in Conflict Management from the University of Windsor, Faculty of Law/Stitt Feld Handy Group.

Dr. Robert Fraser is the President and CSO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.